Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

40.45 +2.36 (+6.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Volume	3,452,003
Open	38.01
Bid (Size)	39.60 (500)
Ask (Size)	40.50 (500)
Prev. Close	38.09
Today's Range	37.43 - 40.58
52wk Range	9.570 - 43.69
Shares Outstanding	105,736,200
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗

November 18, 2025

Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.

Via Benzinga

Performance

YTD	+105.9%	+105.9%
1 Month	+6.4%	+6.4%
3 Month	+94.9%	+94.9%
6 Month	+162.8%	+162.8%
1 Year	+116.2%	+116.2%

More News

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

November 18, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗

September 02, 2025

Via Stocktwits

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

Via Benzinga

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

November 06, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Privium Fund Management Sells Into Strength in Pharma Stock ↗

November 04, 2025

Via The Motley Fool

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

November 04, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 28, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 21, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

October 07, 2025

From Arrowhead Pharmaceuticals

Via Business Wire

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Via Benzinga

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

September 11, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 10, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗

September 05, 2025

Via The Motley Fool

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Via Investor's Business Daily

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 02, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

August 27, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week ↗

August 14, 2025

Via Stocktwits

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives ↗

August 14, 2025

Via Investor's Business Daily

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial ↗

August 14, 2025

Via Stocktwits

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

August 13, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead (ARWR) Q3 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Arrowhead (ARWR) Q3 Revenue Drops 41% ↗

August 07, 2025

Via The Motley Fool

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?

Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market

What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 40.45

When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 11/21/25 04:00 PM ET

What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 4.28B

How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?

Arrowhead Pharmaceuticals, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.